1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cara Therapeutics, Inc. - Product Pipeline Review - 2013

Cara Therapeutics, Inc. - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 21 pages

Cara Therapeutics, Inc. - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “Cara Therapeutics, Inc. - Product Pipeline Review - 2013” provides data on the Cara Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Cara Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Cara Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- Cara Therapeutics, Inc. - Brief Cara Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Cara Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Cara Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Cara Therapeutics, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate Cara Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Cara Therapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Cara Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Cara Therapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Cara Therapeutics, Inc. and identify potential opportunities in those areas.

Table Of Contents

Cara Therapeutics, Inc. - Product Pipeline Review - 2013
Table of Contents 2
List of Figures 3
Cara Therapeutics, Inc. Snapshot 4
Cara Therapeutics, Inc. Overview 4
Key Information 4
Key Facts 4
Cara Therapeutics, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Cara Therapeutics, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Cara Therapeutics, Inc. - Pipeline Products Glance 9
Cara Therapeutics, Inc. Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
Cara Therapeutics, Inc. - Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
Cara Therapeutics, Inc. - Drug Profiles 12
CR-701 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
CR-845 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Cara Therapeutics, Inc. - Pipeline Analysis 15
Cara Therapeutics, Inc. - Pipeline Products by Therapeutic Class 15
Cara Therapeutics, Inc. - Pipeline Products by Route of Administration 16
Cara Therapeutics, Inc. - Pipeline Products By Mechanism of Action 17
Cara Therapeutics, Inc. - Recent Pipeline Updates 18
Cara Therapeutics, Inc. - Locations And Subsidiaries 19
Head Office 19
Appendix 20
Methodology 20
Coverage 20
Secondary Research 20
Primary Research 20
Expert Panel Validation 20
Contact Us 21
Disclaimer 21

List of Tables


Cara Therapeutics, Inc., Key Information 4
Cara Therapeutics, Inc., Key Facts 4
Cara Therapeutics, Inc. - Pipeline by Indication, 2013 6
Cara Therapeutics, Inc. - Pipeline by Stage of Development, 2013 7
Cara Therapeutics, Inc. - Monotherapy Products in Pipeline, 2013 8
Cara Therapeutics, Inc. - Phase II, 2013 9
Cara Therapeutics, Inc. - Phase I, 2013 10
Cara Therapeutics, Inc. - Pre-Clinical, 2013 11
Cara Therapeutics, Inc. - Pipeline By Therapeutic Class, 2013 15
Cara Therapeutics, Inc. - Pipeline By Route of Administration, 2013 16
Cara Therapeutics, Inc. - Pipeline Products By Mechanism of Action, 2013 17
Cara Therapeutics, Inc. - Recent Pipeline Updates, 2013 18

List of Figures


Cara Therapeutics, Inc. - Pipeline by Indication, 2013 6
Cara Therapeutics, Inc. - Pipeline by Stage of Development, 2013 7
Cara Therapeutics, Inc. - Monotherapy Products in Pipeline, 2013 8
Cara Therapeutics, Inc. - Pipeline By Therapeutic Class, 2013 15
Cara Therapeutics, Inc. - Pipeline By Route of Administration, 2013 16
Cara Therapeutics, Inc. - Pipeline Products By Mechanism of Action, 2013 17

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.